Therefore, the authors investigated the usefulness of peak LA longitudinal strain (PALS) in the prediction of upcoming CTRCD after additional trastuzumab therapy in HER2-positive breast cancer patients who did not develop CTRCD after chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.